RESUMO
BACKGROUND: We identified two boys with type 3 renal tubular acidosis (RTA) and growth hormone deficiency and we sought to differentiate them from children with classic type 1 distal RTA. METHODS: We reviewed all children <6 years of age with RTA referred over a 13-year period and compared the growth response to alkali therapy in these two boys and in 28 children with only type 1 distal RTA. RESULTS: All children with type 1 RTA reached the 5th percentile or higher on CDC growth charts within 2 years of alkali therapy. Their mean height standard deviation score (SDS) improved from -1.4 to -0.6 SDS and their mean mid-parental height (MPH) SDS improved from -0.6 to 0 SDS after 2 years. In contrast, the boys with growth hormone deficiency had a height SDS of -1.4 and -2.4 SDS after 2 years of alkali and the MPH SDS were both -2.6 SDS after 2 years of alkali therapy. Growth hormone therapy accelerated their growth to normal levels and led to long-term correction of RTA. CONCLUSIONS: A child with type 1 RTA whose height response after 2 years of alkali therapy is inadequate should undergo provocative growth hormone testing.
Assuntos
Acidose Tubular Renal/complicações , Estatura/efeitos dos fármacos , Transtornos do Crescimento/complicações , Hormônio do Crescimento Humano/deficiência , Pré-Escolar , Transtornos do Crescimento/tratamento farmacológico , Hormônio do Crescimento Humano/administração & dosagem , Hormônio do Crescimento Humano/uso terapêutico , Humanos , Lactente , Masculino , Resultado do TratamentoRESUMO
BACKGROUND AND OBJECTIVES: Chronic kidney disease (estimated glomerular filtration rate <60 ml/min per 1.73 m(2)) and peripheral arterial disease (ankle-brachial index <0.9) independently predict mortality. It was hypothesized that the risk for death is higher in patients with both chronic kidney disease and peripheral arterial disease compared with those with chronic kidney disease or peripheral arterial disease alone. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 1079 patients who had an ankle-brachial index and serum creatinine recorded within 90 d of each other in 1999 were studied retrospectively. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease equation. Patients were categorized into four groups: Chronic kidney disease and peripheral arterial disease, chronic kidney disease alone, peripheral arterial disease alone, or no chronic kidney disease or peripheral arterial disease. RESULTS: The overall 6-yr mortality rate was 28% (n = 284). Patients with both chronic kidney disease and peripheral arterial disease had the highest mortality rate (45%) compared with patients with chronic kidney disease alone (28%), peripheral arterial disease alone (26%), and neither condition (18%). After adjustment for clinical and demographic variables, the chronic kidney disease and peripheral arterial disease group had an increased odds for death when compared with the no chronic kidney disease or peripheral arterial disease group or the single disease groups. CONCLUSIONS: These findings indicate that patients with both chronic kidney disease and peripheral arterial disease have a significantly higher risk for death than patients with either disease alone.
Assuntos
Nefropatias/mortalidade , Doenças Vasculares Periféricas/mortalidade , Idoso , Idoso de 80 Anos ou mais , Tornozelo/irrigação sanguínea , Pressão Sanguínea , Artéria Braquial/fisiopatologia , Doença Crônica , Creatinina/sangue , Feminino , Taxa de Filtração Glomerular , Humanos , Estimativa de Kaplan-Meier , Nefropatias/complicações , Nefropatias/metabolismo , Nefropatias/fisiopatologia , Masculino , Pessoa de Meia-Idade , Razão de Chances , Doenças Vasculares Periféricas/complicações , Doenças Vasculares Periféricas/fisiopatologia , Estudos Retrospectivos , Medição de Risco , Índice de Gravidade de Doença , Fatores de TempoRESUMO
We report a patient with metastatic non-small cell lung cancer who developed renal toxicities manifest as acute renal failure associated with nephrogenic diabetes insipidus and distal renal tubular acidosis following sequential therapy with pemetrexed. The nephrotoxicity occurred concomitantly with severe myelosuppression. We postulate renal tubular toxicity may account for distinct patterns of injury including acute renal failure and tubular cell dysfunction of the distal nephron.
Assuntos
Acidose Tubular Renal/induzido quimicamente , Injúria Renal Aguda/induzido quimicamente , Antimetabólitos Antineoplásicos/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/complicações , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Diabetes Insípido Nefrogênico/induzido quimicamente , Glutamatos/efeitos adversos , Guanina/análogos & derivados , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/tratamento farmacológico , Acidose Tubular Renal/complicações , Injúria Renal Aguda/complicações , Diabetes Insípido Nefrogênico/complicações , Feminino , Taxa de Filtração Glomerular , Guanina/efeitos adversos , Humanos , Túbulos Renais/efeitos dos fármacos , Pessoa de Meia-Idade , PemetrexedeRESUMO
Atheromatous embolization is a multisystem disease complicating advanced atherosclerosis. It occurs most often as a complication of angiography, an endovascular procedure or cardiovascular surgery. Atheromatous embolization can present in a subtle manner where it is often under-recognized, or with catastrophic results including myocardial infarction, strake or acute renal failure. It may mimic other disease processes and often goes underdiagnosed and undertreated. A high clinical suspicion is the key to diagnosis. Atheromatous embolization results in significant morbidity and mortality; therefore, early recognition followed by aggressive management may help to prevent end-organ damage and improve overall clinical outcomes. Management strategies should include risk factor modification, prevention of further insults by discontinuing or avoiding predisposing factors, supportive treatment and interventional or surgical approaches to remove the atheroembolic source. Atheromatous embolization is expected to increase as our population ages and the epidemics of diabetes mellitus and obesity increase.